Immunoglobulin G1 (IgG1) is a type of antibody that plays a crucial role in the immune response by recognizing and binding to specific antigens, such as proteins produced by pathogens. The specific substance mentioned, anti-(human tumor necrosis factor α) (mouse monoclonal BAYX1351), is a monoclonal antibody designed to target and neutralize human tumor necrosis factor alpha (TNF-α), a cytokine involved in systemic inflammation and implicated in various autoimmune diseases. This antibody is composed of two heavy chains (γ1-chain) and two light chains, forming a dimeric structure stabilized by disulfide bonds. The dimeric form enhances its stability and efficacy in therapeutic applications. The CAS number 162774-06-3 uniquely identifies this specific compound, which is utilized in research and clinical settings for its potential to modulate immune responses and treat conditions such as rheumatoid arthritis and inflammatory bowel disease. Overall, this antibody exemplifies the use of monoclonal antibodies in targeted therapy, showcasing their specificity and effectiveness in biomedical applications.

Immunoglobulin G1, anti-(human tumor necrosis factor α) (mouse monoclonal BAYX1351 γ1-chain), disulfide with mouse monoclonal BAYX1351 light chain, dimer

162774-06-3: Immunoglobulin G1 (IgG1) is a type of antibody that plays a crucial role in the immune response by recognizing and binding to specific antigens, such as proteins produced by pathogens. The specific substance mentioned, anti-(human tumor necrosis factor α) (mouse monoclonal BAYX1351), is a monoclonal antibody designed to target and neutralize human tumor necrosis factor alpha (TNF-α), a cytokine involved in systemic inflammation and implicated in various autoimmune diseases. This antibody is composed of two heavy chains (γ1-chain) and two light chains, forming a dimeric structure stabilized by disulfide bonds. The dimeric form enhances its stability and efficacy in therapeutic applications. The CAS number 162774-06-3 uniquely identifies this specific compound, which is utilized in research and clinical settings for its potential to modulate immune responses and treat conditions such as rheumatoid arthritis and inflammatory bowel disease. Overall, this antibody exemplifies the use of monoclonal antibodies in targeted therapy, showcasing their specificity and effectiveness in biomedical applications.

<p>Nerelimomab (BAYX1351), an anti-TNF-α antibody, is utilized in sepsis research [1] [2].</p>

Nerelimomab

<p>Anti-TNF alpha mouse monoclonal antibody; TNF inhibitor</p>

CAS 162774-06-3

Immunoglobulin G1, anti-(human tumor necrosis factor α) (mouse monoclonal BAYX1351 γ1-chain), disulfide with mouse monoclonal BAYX1351 light chain, dimer

Nerelimomab

Ref: TM-T77097

Nerelimomab

Ref: 3D-CLA1229